Cargando…

MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer

Introduction: Chemotherapy is still the standard of care for triple-negative breast cancers (TNBCs). Here, we investigated miR-302b as a therapeutic tool to enhance cisplatin sensitivity in vivo and unraveled the molecular mechanism. Materials and Methods: TNBC-xenografted mice were treated with miR...

Descripción completa

Detalles Bibliográficos
Autores principales: Cataldo, Alessandra, Romero-Cordoba, Sandra, Plantamura, Ilaria, Cosentino, Giulia, Hidalgo-Miranda, Alfredo, Tagliabue, Elda, Iorio, Marilena V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464985/
https://www.ncbi.nlm.nih.gov/pubmed/32806777
http://dx.doi.org/10.3390/cancers12082261
_version_ 1783577487830155264
author Cataldo, Alessandra
Romero-Cordoba, Sandra
Plantamura, Ilaria
Cosentino, Giulia
Hidalgo-Miranda, Alfredo
Tagliabue, Elda
Iorio, Marilena V.
author_facet Cataldo, Alessandra
Romero-Cordoba, Sandra
Plantamura, Ilaria
Cosentino, Giulia
Hidalgo-Miranda, Alfredo
Tagliabue, Elda
Iorio, Marilena V.
author_sort Cataldo, Alessandra
collection PubMed
description Introduction: Chemotherapy is still the standard of care for triple-negative breast cancers (TNBCs). Here, we investigated miR-302b as a therapeutic tool to enhance cisplatin sensitivity in vivo and unraveled the molecular mechanism. Materials and Methods: TNBC-xenografted mice were treated with miR-302b or control, alone or with cisplatin. Genome-wide transcriptome analysis and independent-validation of Integrin Subunit Alpha 6 (ITGA6) expression was assessed on mice tumor samples. Silencing of ITGA6 was performed to evaluate cisplatin response in vitro. Further, potential transcription factors of ITGA6 (E2F transcription facor 1 (E2F1), E2F transcription factor 2 (E2F2), and Yin Yang 1 (YY1)) were explored to define the miRNA molecular mechanism. The miR-302b expression was also assessed in TNBC patients treated with chemotherapy. Results: The miR–302b-cisplatin combination significantly impaired tumor growth versus the control through indirect ITGA6 downregulation. Indeed, ITGA6 was downmodulated in mice treated with miR-302b–cisplatin, and ITGA6 silencing increased drug sensitivity in TNBC cells. In silico analyses and preclinical assays pointed out the regulatory role of the E2F family and YY1 on ITGA6 expression under miR-302b–cisplatin treatment. Finally, miR-302b enrichment correlated with better overall survival in 118 TNBC patients. Conclusion: MiR-302b can be exploited as a new therapeutic tool to improve the response to chemotherapy, modulating the E2F family, YY1, and ITGA6 expression. Moreover, miR-302b could be defined as a new prognostic factor in TNBC patients.
format Online
Article
Text
id pubmed-7464985
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74649852020-09-04 MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer Cataldo, Alessandra Romero-Cordoba, Sandra Plantamura, Ilaria Cosentino, Giulia Hidalgo-Miranda, Alfredo Tagliabue, Elda Iorio, Marilena V. Cancers (Basel) Article Introduction: Chemotherapy is still the standard of care for triple-negative breast cancers (TNBCs). Here, we investigated miR-302b as a therapeutic tool to enhance cisplatin sensitivity in vivo and unraveled the molecular mechanism. Materials and Methods: TNBC-xenografted mice were treated with miR-302b or control, alone or with cisplatin. Genome-wide transcriptome analysis and independent-validation of Integrin Subunit Alpha 6 (ITGA6) expression was assessed on mice tumor samples. Silencing of ITGA6 was performed to evaluate cisplatin response in vitro. Further, potential transcription factors of ITGA6 (E2F transcription facor 1 (E2F1), E2F transcription factor 2 (E2F2), and Yin Yang 1 (YY1)) were explored to define the miRNA molecular mechanism. The miR-302b expression was also assessed in TNBC patients treated with chemotherapy. Results: The miR–302b-cisplatin combination significantly impaired tumor growth versus the control through indirect ITGA6 downregulation. Indeed, ITGA6 was downmodulated in mice treated with miR-302b–cisplatin, and ITGA6 silencing increased drug sensitivity in TNBC cells. In silico analyses and preclinical assays pointed out the regulatory role of the E2F family and YY1 on ITGA6 expression under miR-302b–cisplatin treatment. Finally, miR-302b enrichment correlated with better overall survival in 118 TNBC patients. Conclusion: MiR-302b can be exploited as a new therapeutic tool to improve the response to chemotherapy, modulating the E2F family, YY1, and ITGA6 expression. Moreover, miR-302b could be defined as a new prognostic factor in TNBC patients. MDPI 2020-08-12 /pmc/articles/PMC7464985/ /pubmed/32806777 http://dx.doi.org/10.3390/cancers12082261 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cataldo, Alessandra
Romero-Cordoba, Sandra
Plantamura, Ilaria
Cosentino, Giulia
Hidalgo-Miranda, Alfredo
Tagliabue, Elda
Iorio, Marilena V.
MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
title MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
title_full MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
title_fullStr MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
title_full_unstemmed MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
title_short MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
title_sort mir-302b as a combinatorial therapeutic approach to improve cisplatin chemotherapy efficacy in human triple-negative breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464985/
https://www.ncbi.nlm.nih.gov/pubmed/32806777
http://dx.doi.org/10.3390/cancers12082261
work_keys_str_mv AT cataldoalessandra mir302basacombinatorialtherapeuticapproachtoimprovecisplatinchemotherapyefficacyinhumantriplenegativebreastcancer
AT romerocordobasandra mir302basacombinatorialtherapeuticapproachtoimprovecisplatinchemotherapyefficacyinhumantriplenegativebreastcancer
AT plantamurailaria mir302basacombinatorialtherapeuticapproachtoimprovecisplatinchemotherapyefficacyinhumantriplenegativebreastcancer
AT cosentinogiulia mir302basacombinatorialtherapeuticapproachtoimprovecisplatinchemotherapyefficacyinhumantriplenegativebreastcancer
AT hidalgomirandaalfredo mir302basacombinatorialtherapeuticapproachtoimprovecisplatinchemotherapyefficacyinhumantriplenegativebreastcancer
AT tagliabueelda mir302basacombinatorialtherapeuticapproachtoimprovecisplatinchemotherapyefficacyinhumantriplenegativebreastcancer
AT ioriomarilenav mir302basacombinatorialtherapeuticapproachtoimprovecisplatinchemotherapyefficacyinhumantriplenegativebreastcancer